

## Specification

On page 1, line 13, please delete:

“butyl-1-p-tolyl-1H-pyrazol-5-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea (1)”

and replace with:

--butyl-1-p-tolyl-1H-pyrazol-5-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea (1)--

Same page, delete the entire paragraph beginning on line 17 and replace with:

--1-[*tert*-butyl-1-p-tolyl-1H-pyrazol-5-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea (1) is an therapeutically effective inhibitor of cytokines, which can be used for treating diseases and pathological conditions involving inflammations. This compound is known for example from the US patent US 6,319,921.--

Page 2, delete the entire paragraph beginning on line 5 and replace with:

--Accordingly, the invention relates to an improved process for the preparation of a polymorph of 1-[*tert*-butyl-1-p-tolyl-1H-pyrazol-5-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea (1) by crystallization from an alcohol, wherein the improvement is that crude (1) is treated with ethanol.--

Same page, line 11, please delete:

“1H-pyrazol-5-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea (1) which is”

and replace with:

--1H-pyrazol-5-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea (1) which is--